Scroll Back to Top
Accessibility
Accessibility
Female scientist showing a glass slide that has a sample from a great tumour on it.

Biopharma Solutions

OmniSeq® INSIGHT

Genomic and immune profiling solutions to maximize data from limited samples
 

Comprehensive genomic and immune profiling solutions to advance biomarker-driven development programs

The Labcorp OmniSeq INSIGHT portfolio can help empower your therapeutic development program with valuable insights into cancer-related pathways. With sample-sparing workflows and clear, comprehensive views of biomarker status, our gene expression and genomic profiling services support you from biomarker validation and exploratory endpoint analysis to optimizing patient selection and stratification for clinical trials.

Comprehensive solutions for solid tumor profiling

Icon of a molecule with a magnifying glass above it

523 genes | HRD | MSI | TMB

OmniSeq INSIGHT Genomic Profiling Assay

Comprehensive coverage of genomic alterations across solid tumor types

Icond of a cluster of four different cells

395 genes | 64 validated | HLA

OmniSeq INSIGHT Immune Profiling Assay

Targeted NGS assay for comprehensive immune profiling

Icon of a gene with two dropletts to the left

523 genes | bMSI | bTMB

OmniSeq INSIGHT ctDNA

Pan solid-tumor liquid biopsy CGP for cancer research

Propel cutting-edge therapy development with emerging biomarker insights​

OmniSeq INSIGHT Genomic Profiling is now available with homologous recombination deficiency (HRD) reporting

  • Empower your PARP inhibitor and DNA repair gene pathway-focused development programs
  • Provides a comprehensive genome instability score (GIS) that includes all three critical genomic scars (LOH, TAI, LST) to maximize identification of ​ 
    HRD+ samples​
  • Supports pan-cancer samples for research​ 
View Sample Report(Opens in a new window)
Biopharma OmniSeq INSIGHT lab image

Specifications

AssayOmniSeq INSIGHTOmniSeq INSIGHT ctDNA
Genomic Profiling AssayImmune Profiling Assay
Intended useLDT or RUO*LDT or RUO*RUO†
Targets
  • Full coding sequence of 523 cancer-related genes
    • SNVs, indels, amplifications, translocations
    • HRD, MSI and TMB biomarkers
  • RNA sequencing of 55 genes
    • Fusions and splice variants
  • Expression profiling of 395 immune-related genes (64 clinically validated)
    • PD-L1, HLA Class I gene expression, cancer testis antigens
    • T-cell priming/trafficking, T-cell recognition, T-cell infiltration, cytotoxic T-cells
  • Full coding sequence of 523 cancer-related genes
    • SNVs, indels, amplifications, translocations
    • bMSI and bTMB biomarkers
AnalysisDNA and RNA from FFPE tissueRNA from FFPE tissueCell-free DNA derived from plasma
Sample input

10 mg tissue or

10 x 5 μm unstained slides or

40-100 ng DNA and 20-80 ng RNA

3-5 x 5 μm unstained slides or

RNA as low as 10 ng; 20-80 ng recommended

As low as 10 ng;

20 ng cfDNA recommended

Combined assay with PD-L1 testing: 10 mg tissue or 20x5 μM unstained slides or 40-100 ng DNA and 30-100 ng RNAN/A
Sequencing coverage750x2M reads>1300x de-duplicated depth (with UMIs)
Turnaround time

Prospective testing: as few as 7-10 days;

Exploratory/retrospective testing: SOW dependent

Prospective testing: as few as 7-10 days;

Exploratory/retrospective testing: SOW dependent

As few as 7-10 days
Data outputs (Format)Sequences (FASTQ); alignments (BAM); SNV, indel and CNV variant calls (VCF); MSI, TMB and run QC metrics (JSON); combined variant and run metrics file (TSV)Sequences (FASTQ); alignments (BAM); sample QC, absolute reads, background subtracted read count, RPKM, gene expression rank (CSV); custom bioinformatics signaturesSequences (FASTQ); alignments (BAM); SNV, indel and CNV variant calls (VCF); bMSI, bTMB and run QC metrics (JSON); combined variant and run metrics file (TSV)

*The OmniSeq INSIGHT Genomic and Immune Profiling Assays are intended for research and investigational use. For information about the OmniSeq INSIGHT clinical test (LDT), visit https://oncology.labcorp.com/cancer-care-team/test-menu/omniseq-insight. 

†OmniSeq INSIGHT ctDNA is intended for research use only. Contact your sales representative for additional options.

Select publications
 

Assay validations

Biomarker insights

Labcorp OmniSeq INSIGHT CGIP solutions

Icon of a clipboard with a trending up and down graph

Comprehensive

Broad panels maximize relevant insights from cancer-related variants and immune gene expression
 

Icon of a target with arrow in the middle

Accurate

Optimized workflows provide high coverage, even with low-quality samples, to measure gene and transcript abundance and identify known and novel features
 

Icon of a badge with a checkmark in the middle

Reliable

Highly optimized and robust validation to ensure optimal performance in low-quality samples

Contact Us to Learn More

To submit a complaint related to this offering, please complete this form.

Form